CraniUS began in May 2021 in Baltimore, MD
CraniUS was developed as a byproduct of the emerging field known as “Neuroplastic and Reconstructive Surgery”, through the vision, insight, and pioneering work of Dr. Chad Gordon. Our flagship device, known as the NeuroPASS, is being specifically developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective. CraniUS utilizes a novel pump design and wireless charging technology to enable long-term and direct medicine administration via CED (convection-enhanced delivery), an effective method of medicine delivery first introduced by the National Institute of Health (NIH).
NeuroPASS Drug Delivery
Is a refillable drug delivery system engineered to bypass the blood-brain barrier. This fully implantable device is designed to provide precise delivery of therapeutic agents directly to targeted areas, minimizing systemic side effects and maximizing treatment effectiveness. This innovative technology has the potential to unlock new treatment options and transform the lives of patients facing aggressive brain tumors and other complex neurological conditions.
Treatment Flow Benefits:
Delivers targeted microdoses directly to the tumor area, minimizing systemic side effects.
Provides continuous, controlled drug release for sustained treatment effectiveness.
Meet our team
Forward-thinkers driving patient and user-focused innovation
By bringing diverse skills together, we advance the quality and output of CraniUS
NeuroPASS™ Differentiators
Delivers the right drug to the right location, fully bypassing the blood-brain barrier.
